NCT05690984 2026-03-16
EMAT
Medical College of Wisconsin
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT06203912 2026-03-05
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03617731 2026-02-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Phase 3 Active not recruiting
NCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT04653246 2025-12-23
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting